RenovoRx, Inc. (RNXT) Stock Profile — Insider Trades & Financials

Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($20K, 1 buy vs 0 sales)

Revenue$563.0K

Net Income-$3.5M

EPS$-0.09

Gross Margin85.1%

Market Cap$41.0M

Price Performance

Historical data including institutional events

Company Profile

Shaun Bagai

CEO & Executive Director

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Founded: 2012
Employees: 10
Headquarters: Mountain View, California, United States
Website: renovorx.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($20K, 1 buy vs 0 sales)

Revenue$563.0K

Net Income-$3.5M

EPS$-0.09

Gross Margin85.1%

Market Cap$41.0M

Price Performance

Historical data including institutional events

Company Profile

Shaun Bagai

CEO & Executive Director

Founded: 2012
Employees: 10
Headquarters: Mountain View, California, United States
Website: renovorx.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

RenovoRx, Inc.

Price Performance

Company Profile

The morning brief, before the bell.

RenovoRx, Inc.

Price Performance

Company Profile